It is definitely the season to be jolly for Genfit SA after signing a lucrative licensing deal with fellow French firm Ipsen SA for elafibranor for the rare liver disease primary biliary cholangitis, some 18 months after the compound was discontinued as a potential treatment for NASH.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?